Pharmaceuticals
France Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The France Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US$30 Mn in 2022 and is predicted to grow at a CAGR of 4.80% from 2023 to 2030, reaching US million by 2030. The key drivers of this industry include the upward trend in the incidence of autosomal dominant polycystic kidney disease, strong healthcare infrastructure and other factors. The industry is primarily dominated by players such as Otsuka, Sanofi, Roche, Biogen, AstraZeneca, Janssen among others
Buy Now
France Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The France Autosomal Dominant Polycystic Kidney Disease Therapeutics Market is at around US $ 30.3 Mn in 2022 and is projected to reach US $44.1 Mn in 2030, exhibiting a CAGR of 4.80% during the forecast period.
A genetic disease called autosomal dominant polycystic kidney disease (ADPKD) affects multiple organs and is caused by mutations in PKD1 and PKD2 genes. This leads to numerous cysts forming in the kidneys, causing them to enlarge (renomegaly). In most cases, ADPKD progresses to kidney failure (ESKD). Symptoms include pain, frequent infections, and fatigue. While no cure exists for this rare disease, treatment focuses on preventing complications and managing symptoms. Tolvaptan (Jinarc) from Otsuka Pharmaceutical is the only approved drug, acting as a vasopressin blocker to slow cyst growth in some patients. Other options include pain management and lifestyle changes for prevention.
France is a country located in Western Europe. The incidence of ADPKD is around 57/1,00,000 individuals in France. There is an anticipated upward trend in the prevalence of ADPKD in France due to advancements in diagnostic modalities that reduce the number of missed detections. There is no proportional increase in the younger age groups as the population ages, indicating a demographic sift and increased investment in curative and preventive research. The market is therefore driven by major factors like increased prevalence, research and development, and strong healthcare infrastructure in the industry. However, conditions such as high costs of treatment and limited treatment options other than Tolvaptan, among other factors, hinder the growth and potential of the market.
Market Dynamics
Market Growth Drivers
Surge in the prevalence of ADPKD: The incidence of APDPKD suggests that the overall incidence is 57/1,00,000 individuals in France. These estimates are anticipated to result in patients requiring treatment like dialysis, resulting in growth of the market.
Strong healthcare infrastructure: France's robust healthcare system includes modern medical institutes and a proficient nephrology workforce, ensuring ADPKD patients have access to specialized care. Public healthcare initiatives such as Assurance Maladie (French Health Insurance) offer coverage for medications and treatments, enhancing affordability and patient accessibility.
Research and development: France actively engages in global ADPKD research, conducting randomized controlled trials (RCTs) and cohort studies, and collaborating among research institutions and pharmaceutical entities to develop innovative therapies and personalized medicine strategies
Patient Advocacy: The Association Française PKD (French PKD Association) and other active patient advocacy groups raise awareness and educate patients, allowing increased access to diagnosis, treatment, and research opportunities, which results in expansion of the market.
Market Restraints
High costs of treatment: Treatments for ADPKD, such as Tolvaptans, can be costly, causing a considerable financial burden on both patients and the healthcare system. These out-of-pocket expenditures hinder treatment, especially for those with inadequate insurance coverage, and can result in the non-compliance of patients, distorting the growth of the Mexican market.
Limited treatment options: Despite the emergence of new therapies, there's currently no cure for ADPKD, and existing treatments solely address symptoms. The absence of definitive solutions to manage disease advancement might deter certain patients from pursuing treatment and result in non-compliance
Health system disparities: The inequitable distribution of specialized nephrologists and advanced diagnostic resources across various French regions results in uneven patient care and treatment options. These disparities may contribute to unequal patient outcomes and impede market expansion in underserved areas.
Notable Updates
October, 2023, Health authorities in France streamlined the registration process for a novel oral medication intended for ADPKD, potentially expediting its availability to patients. This advancement signifies a positive stride toward enhancing access to innovative treatment choices.
July, 2023, In France, two late-stage clinical trials for potential gene therapy techniques for ADPKD began patient recruitment, enhancing the possibility of French patients accessing novel therapeutics.
Healthcare Policies and Regulatory Landscape
France's healthcare system navigates through a complex web of authorities and regulations. The French National Agency for Medicines and Health Products Safety (ANSM) reigns supreme as the primary body for all healthcare products, including pharmaceuticals. ANSM meticulously regulates, monitors, and grants licenses for everything health-related, ensuring quality and safety throughout the therapeutic landscape.
France's healthcare system comprises both the public and private spheres. The Ministry of Social Affairs, Health, and Women's Rights leads the public sector, crafting the national health strategy and orchestrating healthcare services. This ministry wields the power to define and implement government policies concerning public health, ensuring everyone has access to quality care. To operate in France, companies must abide by ANSM's strict guidelines. Before entering the market, therapeutics need ANSM's stamp of approval through registration and a marketing license. For this, companies must submit comprehensive data proving their product's effectiveness, safety, and quality, leaving nothing to chance.
France's robust regulatory framework and resilient healthcare system create a thriving environment for businesses to flourish. The nation's diverse healthcare landscape offers a treasure trove of opportunities for companies across both the public and private sectors, making it fertile ground for innovation and growth.
Competitive Landscape
Key Players
- Otsuka Pharmaceutical Co., Ltd
- Janssen Pharmaceuticals
- Reata Pharmaceuticals
- AbbVie Inc
- Sanofi
- Pierre Fabre Laboratories
- Biogen Inc
- Pfizer
- Roche
- AstraZeneca
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
France Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Segmentation
By Treatment
- Pain & Inflammation Treatment
- Kidney Stone Treatment
- Urinary Tract Infection Treatment
- Kidney Failure Treatment
By Route of Administration
- Oral
- Parenteral
- Others
By End User
- Hospitals
- Speciality Clinics
- Surgical Centres
- Others
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
- Analyzing historical proprietary data collected from multiple projects.
- Regularly updating our existing data sets with new findings and trends.
- Ensuring data consistency and accuracy through rigorous validation processes.
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
- Searching through academic conferences, published research, citations, and social media platforms
- Collecting and compiling diverse data to build a comprehensive and detailed database
- Continuously updating our database with new information to ensure its relevance and accuracy
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
- Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
- Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
- Continuously refreshing our database to ensure that the information remains current and reliable.
- Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
- Merging historical data from secondary research with real-time data from primary research.
- Conducting thorough data validation and cleansing to remove inconsistencies and errors.
- Organizing data into a structured format that is easily accessible and usable for various applications.
- Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
Related reports (by category)
Pharmaceuticals
South Africa Ovarian Cancer Drugs Market Analysis
Pharmaceuticals
Brazil Anemia Therapeutics Market Analysis
Related reports (by geography)
Digital Health
France Electronic Health Records Market Analysis
Rare Diseases
France Myasthenia Gravis Drugs Market Analysis
Rare Diseases
France POMC Genetic Obesity Drugs Market Analysis
Rare Diseases
